Email
Hospital Circular 09/12
Date Issued: 30 April 2012
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 May 2012.
New Items
Tocilizumab
| 1476Q | Concentrate for injection 80mg in 4mL |
1 | Actemra | RO | $186.88 |
| 1481Y | Concentrate for injection 200mg in 10mL |
1 | Actemra | RO | $467.20 |
| 1482B | Concentrate for injection 400mg in 20mL |
1 | Actemra | RO | $934.40 |
Complex Authority Required- listing for severe active systemic juvenile idiopathic arthritis
New Brands
Doxorubicin Hydrochloride, Pegylated Liposomal
| 5705G | Suspension for IV infusion 20mg in 10mL |
Lipodox | 4 | 5 | ZF | $2,491.96 |
Mycophenolate Mofetil
| 9502D | Tablet 500mg | 300 | 5 | Pharmacor Mycophenolate | CR | $933.54 |
Deleted items
Darunavir
| 5652L | Tablet 300mg (as ethanolate) | Prezista |
Etravirine
| 5736X | Tablet 100mg | Intelence |
Further information on the changes including the full restrictions can be found at www.health.vic.gov.au/hsdp or http://www.pbs.gov.au/browse/section100-hb
Maree Guyatt
Director
Integrated Care
